Personalized Cancer Vaccines: From Lab to Patient
A man built a cancer vaccine for his dog. Then he open-sourced the blueprint. Here's how personalized mRNA cancer vaccines work — from tumor biopsy to syringe — in 8 steps.
A Dog, a Diagnosis, and a Lab Notebook
When a pet owner's dog was diagnosed with cancer, he didn't just accept the prognosis. He built a personalized cancer vaccine — tailored specifically to his dog's tumor mutations.
From Pet Project to Open-Source Guide
Phil Fung, a former lab startup founder, documented the entire process and published it as OpenVaxx — a free, open-source guide to producing personalized mRNA cancer vaccines. It covers every step from tumor sequencing to the final vial, using open-source software and commercially available benchtop lab equipment. The guide is released under the Apache 2.0 license.
What Is a Personalized Cancer Vaccine?
Unlike traditional vaccines that prevent infection, personalized cancer vaccines are therapeutic — they train your immune system to attack cancer cells that are already in your body.
Every tumor is genetically unique. It accumulates mutations that produce abnormal proteins called neoantigens — molecular flags that don't exist in healthy tissue. A personalized cancer vaccine encodes these neoantigens into synthetic mRNA, teaching the immune system to recognize and destroy cells displaying those flags.
The process follows a logical chain:
The remarkable part: the software to do most of the intellectual work is already open-source and freely available. The hardware is commercially available, and each step can be outsourced to contract labs. The barrier isn't knowledge — it's access, training, and regulation.
8 Steps from Tumor to Vaccine
The OpenVaxx pipeline splits into two halves: a digital pipeline that converts biological samples into a computer-designed mRNA blueprint, and a physical pipeline that turns that blueprint into a vial of vaccine.
The Digital Pipeline (Steps 1-4)
The upstream pipeline is almost entirely software. Once you have sequencing data, the rest runs on open-source tools on a standard workstation. This is where the democratization is happening.
Step 1: Genome Sequencing
Converting biology to data
The sequencer reads three samples: normal blood DNA (baseline, 30-50X depth), tumor DNA (deep coverage at 100-500X to catch rare mutations), and tumor RNA (50-100M reads to verify mutations are actually expressed). A separate analysis derives the patient's HLA profile — their immune system's "lock configuration."
Step 2: Variant Calling
Subtracting healthy from tumor
GATK Mutect2 aligns sequencing reads to the human reference genome, then mathematically subtracts normal DNA from tumor DNA to isolate somatic mutations — changes that exist only in the cancer. The output is a filtered list of high-confidence, tumor-only mutations.
Step 3: Neoantigen Prediction
AI picks the immune targets
pVACseq feeds mutations through MHCflurry neural networks to predict which peptide fragments will bind most strongly to the patient's specific HLA receptors. Stronger binding = more likely the immune system will recognize and attack cells with that mutation. RNA expression data filters out mutations that aren't actually active.
Step 4: mRNA Design
Compiling the vaccine blueprint
pVACvector strings the top neoantigen targets together with linker sequences, adds structural components (5' UTR, Kozak sequence, start codon, stop codon, 3' UTR, poly-A tail), then LinearDesign optimizes codon usage for maximum mRNA stability and translational efficiency.
The Physical Pipeline (Steps 5-8)
This is where digital meets physical. The downstream pipeline requires specialized lab equipment, biosafety protocols, and quality control — the expensive half. Each step can be outsourced to contract research organizations (CROs).
Step 5: DNA Synthesis
Printing the physical master copy
A benchtop DNA synthesizer converts the digital .FASTA blueprint back into physical DNA. Two routes are available: cell-free linear synthesis (faster, ~1-2 days) or traditional plasmid-based cloning via E. coli (24-48 hours additional). The output is purified, linearized DNA template ready for transcription.
Step 6: In Vitro Transcription (IVT)
DNA → functional mRNA
Continuous-flow IVT bioreactors read the DNA template and print the corresponding mRNA strand. Key modifications: N1-methylpseudouridine replaces standard uridine (the same immune-cloaking trick used in Pfizer/Moderna COVID vaccines), and CleanCap® AG adds a 5' cap for human cell recognition. Post-transcription cleanup includes DNase I digestion and mRNA purification.
Step 7: LNP Encapsulation
Wrapping mRNA for cell delivery
Naked mRNA is fragile and can't enter cells on its own. Microfluidic mixing forces negatively charged mRNA and positively charged lipids into self-assembling nanoparticles (60-100nm). The four-lipid cocktail includes an ionizable lipid (e.g., ALC-0315), PEG-lipid, DSPC helper lipid, and cholesterol — the same LNP formula proven in billions of COVID vaccine doses.
Step 8: Quality Control + Filling
Verification and final vials
Dynamic Light Scattering (DLS) measures particle diameter to verify the nanoparticles are in the therapeutic 60-100nm range. Tangential Flow Filtration (TFF) removes the toxic ethanol used during mixing and buffer-exchanges into a cryoprotectant. RiboGreen assay quantifies encapsulation efficiency. Final output: ~10 sterile glass vials at 100µg/mL, stored at -80°C.
Open-Source Tools That Make This Possible
The digital half of the pipeline runs entirely on free, open-source software maintained by major research institutions. These tools are used in real clinical programs — they aren't experimental toys.
Cost Breakdown: In-House vs. Outsourced
Building a full in-house lab costs roughly $800K-$1M in equipment — but that enables production for many patients. The outsourced route costs approximately $5,000-$15,000 per patient.
| Step | Equipment (In-House) | Per-Patient (Outsourced) |
|---|---|---|
| 1. Genome Sequencing | ~$300K (Illumina NextSeq) | ~$2,500 |
| 2. Variant Calling | Standard workstation | $0 (open source) |
| 3. Neoantigen Prediction | Standard workstation | $0 (open source) |
| 4. mRNA Design | Standard workstation | $0 (open source) |
| 5. DNA Synthesis | ~$100K (BioXp 3250) | ~$200-900 |
| 6. IVT (mRNA Synthesis) | ~$250K (NTxscribe) | ~$1,000-3,000 |
| 7. LNP Encapsulation | ~$150K (NanoAssemblr) | ~$2,000-5,000 |
| 8. QC + Filling | ~$80K (Stunner + TFF) | ~$1,000-3,000 |
| Total | ~$880K | ~$6,700-$14,400 |
* Outsourced costs are estimates based on publicly available pricing from CROs and academic facilities. Actual costs vary by provider, volume, and complexity. Steps 2-4 cost nothing because the software is open-source.
Cost Distribution (Outsourced Route)
How This Relates to Peptides & Immunotherapy
If you've been following the peptide research space, personalized cancer vaccines are a natural extension of the same principles. Here's the connection:
Neoantigens are peptides. The targets identified in Step 3 are short peptide sequences (typically 8-11 amino acids for MHC Class I) that the immune system can recognize. The entire field of neoantigen prediction is fundamentally peptide science — predicting which peptide fragments will bind to immune receptors.
Thymosin Alpha-1 and immunotherapy. Peptides like Thymosin Alpha-1 (Tα1) are already used as immune modulators in cancer therapy — they enhance T-cell function, the same immune cells that personalized vaccines aim to activate. The vaccine provides the target; immunomodulatory peptides ensure the immune system is equipped to respond.
BPC-157 and recovery. Cancer treatments are brutal on the body. Peptides like BPC-157 and TB-500 are studied for their tissue-healing and anti-inflammatory properties — relevant for patients recovering from biopsies, surgeries, and the immune responses triggered by cancer vaccines.
The Regulatory Landscape
Having the technical capability to produce a personalized cancer vaccine is one thing. Having the legal authority to administer it is another entirely.
✅ What's Real
- The software pipeline works and is used in clinical research programs worldwide
- Multiple companies have active Phase II/III clinical trials with personalized mRNA cancer vaccines
- BioNTech's autogene cevumeran showed promising results in pancreatic cancer (Phase I)
- Moderna's mRNA-4157 (V940) + Keytruda showed 44% reduction in recurrence for melanoma (Phase IIb)
- All equipment is commercially available and legally purchasable
⚠️ What's Missing
- No personalized mRNA cancer vaccine has FDA approval yet (as of early 2026)
- Administering an unapproved biologic is illegal in most jurisdictions
- GMP (Good Manufacturing Practice) compliance requires certified facilities
- Quality control for injectables has standards far beyond what a private lab can typically meet
- Endotoxin testing, sterility assurance, and potency verification require specialized equipment and protocols
The gap between "technically possible" and "legally/safely administrable" is significant. This guide exists to explain the science and engineering — not to provide a recipe for DIY medicine.
Companies Building Personalized Cancer Vaccines
Several major biotech companies are racing to bring individualized mRNA cancer vaccines to market. These programs use the same fundamental pipeline described above, at pharmaceutical scale with GMP compliance.
Recommended Products
Educational resources and lab safety equipment related to immunotherapy and mRNA science.
Affiliate links help support HighPeptides at no extra cost to you.
Explore More on HighPeptides
Frequently Asked Questions
⚠️ Critical Disclaimer — Read Carefully
This page is for educational and informational purposes only. It is not medical advice, and it is not a guide for producing vaccines or any other biologic product for human or animal use.
Severe biological hazards: Working with human biological samples, recombinant DNA, mRNA, lipid nanoparticles, and injectable products carries serious risks including infection, contamination, endotoxin exposure, and allergic reactions. These processes require BSL-2+ laboratory facilities, trained personnel, and institutional oversight.
Legal restrictions: Manufacturing and administering unapproved biological products is illegal in most jurisdictions. Clinical use of personalized cancer vaccines requires Investigational New Drug (IND) applications, Institutional Review Board (IRB) approval, and compliance with Good Manufacturing Practice (GMP) regulations.
Not a recipe: This article describes the scientific principles and engineering steps involved in personalized mRNA vaccine production. It deliberately omits critical details related to sterility assurance, endotoxin testing, potency assays, and GMP compliance that are required for any product intended for administration.
Consult professionals: If you or someone you know is interested in personalized cancer vaccine therapy, consult with qualified oncologists at major cancer centers where clinical trials are available. Do not attempt DIY production of any injectable biologic product.
Source material: Technical details in this article are based on the OpenVaxx guide by Phil Fung (Apache 2.0 License), combined with publicly available information from equipment manufacturers and research publications. HighPeptides is not affiliated with OpenVaxx.